Tempest Therapeutics Faces Nasdaq Delisting Risk on Equity & Governance Non-Compliance

summarizeSummary

Tempest Therapeutics received multiple Nasdaq deficiency notices for failing to meet minimum stockholders' equity and independent director requirements, putting its listing at risk.

check_boxKey Events

• Nasdaq Deficiency for Stockholders' Equity

  The company reported stockholders' equity of $822,000, significantly below Nasdaq's $2.5 million minimum requirement for continued listing. This follows a recent Q1 2026 report disclosing a $27.7 million net loss and a 'going concern' warning.

• Governance Non-Compliance

  Due to recent director resignations (disclosed in a separate 8-K), the company no longer meets Nasdaq's requirements for a majority independent board and independent audit, compensation, and nominating committees. The company is not eligible for a standard cure period due to multiple vacancies.

• Delisting Risk

  Tempest Therapeutics has 45 calendar days (until July 6, 2026) to submit a plan to regain compliance for both the equity and governance deficiencies. Failure to satisfy these requirements could lead to delisting from the Nasdaq Capital Market.

auto_awesomeAnalysis

This 8-K reveals critical compliance failures that significantly heighten Tempest Therapeutics' delisting risk. The company's stockholders' equity is far below Nasdaq's minimum, a direct reflection of its ongoing financial distress and 'going concern' warning. Compounding this, recent director resignations have left the board non-compliant with independent director rules, indicating governance instability. The company's ability to submit an acceptable compliance plan and regain compliance within the tight deadlines will be crucial for its continued listing on Nasdaq.